"...has a newsletter recommended them?"
I don't know @gmac, but I can understand why an astute newsletter editor might be focussing on CTE:
1. Uncertainty about Cell Care sell-down depressing the SP now removed;
2. New substantial shareholder announcement imminent;
3. Company share-buy back scheme to start in mid-April;
4. Cash backing of $4.3m;
5. Enterprise value at a humble ~$6m;
6. No debt;
7. First half revenue up 18.5% after a 30% rise in clinical trials revenue;
8. Pivotal and unique moated exposure to the national clinical trials industry and the exploding medicinal cannabis market.
And all of this for a stock that's ~50% below its 52 week high. Conclusion: I see scope for material improvement in the SP.
- Forums
- ASX - By Stock
- CTE
- Ann: Change in substantial holding
Ann: Change in substantial holding, page-4
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CTE (ASX) to my watchlist
|
|||||
Last
$1.12 |
Change
0.020(1.82%) |
Mkt cap ! $54.66M |
Open | High | Low | Value | Volume |
$1.12 | $1.12 | $1.12 | $409 | 365 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 33 | $1.12 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.15 | 10000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 33 | 1.120 |
1 | 2000 | 1.030 |
1 | 22000 | 0.980 |
2 | 1270 | 0.810 |
1 | 10000 | 0.795 |
Price($) | Vol. | No. |
---|---|---|
1.150 | 10000 | 1 |
1.180 | 650 | 1 |
1.250 | 54000 | 2 |
1.350 | 15000 | 1 |
1.500 | 50 | 1 |
Last trade - 11.00am 24/06/2024 (20 minute delay) ? |
Featured News
CTE (ASX) Chart |